Interaction of proton pump inhibitors with cytochromes P450: Consequences for drug interactions

Yale Journal of Biology and Medicine

Volumn 69, Issue 3, 1996, Pages 203-209

  Meyer, Urs A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH; CAFFEINE; CARBAMAZEPINE; CYTOCHROME P450; DIAZEPAM; DRUG METABOLIZING ENZYME; LANSOPRAZOLE; MEPHENYTOIN; METHOTREXATE; OMEPRAZOLE; OXIDOREDUCTASE; OXYGENASE; PANTOPRAZOLE; PHENAZONE; PHENYTOIN; PROTON PUMP INHIBITOR; SULFOTRANSFERASE; THEOPHYLLINE;

COMPETITIVE INHIBITION; DEMETHYLATION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME INDUCTION; ENZYME MECHANISM; ENZYME POLYMORPHISM; ENZYME SUBSTRATE COMPLEX; GENE MUTATION; HUMAN; LIVER CELL CULTURE; LIVER MICROSOME; PHENOTYPE; REVIEW;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; PROTON PUMPS;

EID: 0030432011     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Wilde, M.I. and McTavis, D. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorder. Drug 48:91-132, 1994.
2. Delhotal Landes, B., Petite, J.P., and Flouvat, B. Clinical pharmacokinetics of lansoprazole. Clin. Pharmacokinet. 28:458-470, 1995.
3. Huber, R., Kohl, B., Sachs, G., Senn-Bilfinger, J., Simon, W.A., and Sturm, E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment. Pharmacol. Ther. 9:363-378, 1995.
4. Kromer, W. Similarities and differences in the properties of substituted benzimidazoles. a comparison between pantoprazole and related compounds. Digestion 56:443-454, 1995.
5. Andersson, T., Miners, J.O., Veronese, M.E., Tassaneeyakul, W., Tassaneeyakul, W., Meyer, U.A., and Birkett, DJ. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36:521-530, 1993.
6. Andersson, T., Miners, J.O., Veronese, M.E., and Birkett, D.J. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 37:597-604, 1994.
7. Andersson, T., Regårdh, C.-G., Lou, Y.-Ch., Zhang, Y., Dahl, M.-L., and Bertilsson, L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monit. 12:415-146, 1990.
8. Andersson, T., Regårdh, C.-G., Lou, Y.-Ch., Zhang, Y., Dahl, M.-L., and Bertilsson, L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2:25-31, 1992.
9. Chiba, K., Kobayashi, K., Manabe, K., Tani, M., Kamataki, T., and Ishizaki, T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Therap. 266:52-59, 1993.
10. Balian, J.D., Sukhova, N., Harris, J.W., Hewett, J., Pickle, L., Goldstein, J.A., Woosley, R.L., and Flockhart, D.A. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin. Pharmacother. Therap. 57:662-669, 1995.
11. Pichard, L., Curi-Pedrosa, R., bonfils, C., Jacqz-Aigrain, E., Domergue, J., Joyeux, H., Cosme, J., Guengerich, F.P., and Maurel, P. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Molec. Pharmacol. 47:410-418, 1995.
12. Meyer, U.A. Cytochrome P450 in Human Drug Metabolism: How Much is Predictable? In: Waterman, Hildebrand, eds. Assessment of the use of single cytochrome P450 enzymes in drug research. Berlin, Heidelberg, New York:Springer Verlag; 1994, pp. 43-56.
13. Guengerich, F.P. Human cytochrome P450 enzymes. In: de Montellano, O., ed. Cytochrome P450, Structure, Mechanism, and Biochemistry. 2nd edition, New York & London: Plenum Press; 1995, pp. 473-535.
14. Meyer, U.A. and Zanger, U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann. Rev. Pharmacol. Toxicol. 37:269-296, 1997.
15. De Morais, S.M.F., Wilkinson, G.R., Blaisdell, J., Nakamura, K., Meyer U.A. and Goldstein, J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269:15419-15422, 1994.
16. De Morais, S.M.F., Wilkinson, G.R., Blaisdell, J., Meyer, U.A., Nakamura, K., and Goldstein, J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46:594-598, 1994.
17. Sohn, D.-R., Kobayashi, K., Chiba, K., Lee, K.-H., Shin, S.-G., and Ishizaki, T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an oriental population. J. Pharm. Exp. Ther. 262:1195-1202, 1992.
18. Chang, M., Tybring, G., Dahl, M.-L., Götharson, E., Sagar, M., Seensalu, R., and Bertilsson, L. Interphenotype differences in disposition and effect on gastrin levels of omeprazole - suitability of omeprazole as a probe for CYP2C19. Br. J. Clin. Pharmacol. 39:511-518, 1995.
19. Ishizaki, T., Sohn, D.-R., Kobayashi, K., Chiba, K., Lee, K.H., Shin, S.-G., Andersson, T., Regårdh, C.-G., Lou, Y.-C., Zhang, Y., Dahl, M.-L., and Bertilsson, L. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Therap. Drug Monit. 16:214-215, 1994.
20. Price Evans, D.A., Krahn, P., and Narayanan, N. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenet. 5:64-71, 1995.
21. Diaz, D., Fabre, I., Daujat, M., Saint Aubert, B., Bones, P., Michel, H., and Maurel, P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterol. 99:737-747, 1990.
22. McDonnell, W.M. Scheiman, J.M., and Traber, P.G. Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterol. 103:1509-1516, 1992.
23. Buchthal, J., Grund, K.E., Buchmann, A., Schrenk, D., Beaune, P., and Bock, K.W. Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa. Eur. J. Clin. Pharmacol. 47:431-435, 1995.
24. Rost, K.L. and Roots, I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios. Coincidence with plasma clearance and breath test. Clin. Pharmacol. Therap. 55:402-411, 1994.
25. Rost, K.L., Brösicke, H., Heinemeyer, G., and Roots, I. Specific and Dose-dependent enzyme induction by omeprazole in human beings. Hepatol. 20:1204-1212, 1994.
26. Kokufu, T., Ihara, N., Sugioka, N., Koyama, H., Ohta, T., Mori, S., and Nakajima, K. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur. J. Clin. Pharmacol. 48:391-395, 1995.
27. Curi-Pedrosa, R., Daujat, M., Pichard, L., Ourlin, J.C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., Fourtanier, G., and Maurel, P. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Therap. 269:384-392, 1994.
28. Daujat, M., Peryt, B., Lesca, P., Fourtanier, G., Domergue, J., and Maurel, P. Omeprazole, and inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochem. Biophys. Res. Comm. 188:820-825, 1992.
29. Quattrochi, L.C. and Tukey, R.H, Nuclear uptake of the Ah (Dioxin) receptor in response to omeprazole: transcriptional activation of the human CYP1A1 gene. Mol. Pharmacol. 43:504-508, 1993.
30. Steinijans, V.W., Huber, R., Harmann, M., Zech, K., Bliesath, H., Wurst, W., and Radtke, H.W. Lack of pantoprazole drug interactions in man. Internat. J. Clin. Pharmacol. Ther. 32:385-399, 1994.
31. Hartmann, M., Bliesath, H., Zech, K., Koch, H., Steinijans, V.W., Wurst, W., and Mascher, H. Pantoprazole does not influence CYP1A2 activity in man. Gastroenterol. 108(suppl.):A 109, 1995.
32. Andersson, T., Cederberg, Ch., Edvardsson, G., Heggelund A., and Lundborg, P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 47:79-85, 1990.
33. Caraco, Y., Tateishi, T., and Wood, A.J.J. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin. Pharmacol. Ther. 58:62-72, 1995.
34. Lefebvre, R.A., Flouvat, B., Karolac-Tamisier, S., Moerman, E., and van Ganse, E. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin. Pharmacol. Ther. 52(5):458-463, 1992.
35. Gugler, R., Hartmann, M., and Rudi, J. Lack of interaction of pantoprazole and diazepam in man. Gastroenterol. 102:A77, 1992.
36. Gugler, R. and Jensen, J.C. Omeprazole inhibits oxidative drug metabolism - studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterol. 89:1235-1241, 1985.
37. Naidu, M.U.R., Shobha, J.C., Dixit, V.K., Kumar, A., Kumar, T.R., Sekhar, K.R., and Sekhar, E.Ch. Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest. 7:8-12, 1994.
38. Tucker, G.T. The interaction of proton pump inhibitors with cytochromes P450. Aliment. Pharmacol. Ther. 8:33-38, 1994.